This hypothesis suggests that inhibition of either FcγR signaling or specific intracellular signal transduction events downstream of FcγR-IgG interaction, such as NF-κB activation, may be viable therapeutic strategies to slow or prevent the progression of human PD. This evidence concerns the gene FCGR2A and Parkinson disease.